Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study

American Journal of Clinical Dermatology

Volumn 11, Issue 5, 2010, Pages 343-350

  Bovenschen, H Jorn ^a   Langewouters, Annechien M G ^a   Van De Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD161 ANTIGEN; CD94 ANTIGEN; FUMARIC ACID DIMETHYL ESTER; KI 67 ANTIGEN; DERMATOLOGICAL AGENT; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DERMIS; EPIDERMIS; EPIDERMIS CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS SEVERITY INDEX; SKIN BIOPSY; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; CELL DIFFERENTIATION; CELL PROLIFERATION; DERMATOLOGIC AGENTS; DERMIS; EPIDERMIS; FEMALE; FUMARATES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PSORIASIS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS;

EID: 77954800370     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11533240-000000000-00000     Document Type: Article

References (36)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23
2. Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8
3. Valdimarsson H, Baker BS, Jonsdottir I, et al. Psoriasis: a disease of abnormal proliferation induced by T lymphocytes. Immunol Today 1986; 7: 256-259
4. Prinz JC, Gross B, Vollmer S, et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro. Eur J Immunol 1994; 24: 593-598
5. Bovenschen HJ, van Vlijmen-Willems IM, van de Kerkhof PC, et al. Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in psoriasis. Dermatology 2006; 213 (2): 111-117
6. Bovenschen HJ, VissersWH, Seyger MM, et al. Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment. Acta Derm Venereol 2005; 85 (2): 113-117
7. Bovenschen HJ, Seyger MM, Van de Kerkhof PC. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 2005; 153 (1): 72-78
8. Sanders ME, Makgoba MW, Sharrow SO, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and have three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-g production. J Immunol 1988; 140: 1401-1407
9. Wallace DL, Beverley PC. Phenotypic changes associated with activation of CD45RA+ and CD45RO+ T cells. Immunology 1990; 69: 460-467
10. Nickoloff BJ, Wrone-Smith T, Bonish B, et al. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes. Arch Dermatol 1999; 135: 546-552
11. Nickoloff BJ, Bonish B, Huang BB, et al. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model. J Dermatol Sci 2000; 24: 212-225
12. Cameron AL, Kirby B, Fei W, et al. Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res 2002; 294: 363-369
13. Takahashi T, Dejbakhsh-Jones S, Strober S. Expression of CD161 (NKRP1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol 2006 Jan 1; 176 (1): 211-216
14. Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16: 359-393
15. Lopez-Botet M, Bellon T, Llano M, et al. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 2000; 61: 7-17 (Pubitemid 30058762)
16. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999; 104: 1161-1164
17. Vissers WH, Arndtz CH, Muys L, et al. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 2004; 150 (5): 852-859
18. Van Erp PE, de Mare S, Rijzewijk JJ, et al. A sequential double immunoenzymic staining procedure to obtain cell kinetic information in normal and hyperproliferative epidermis. Histochem J 1989; 21: 343-347
19. Mommers JM, van Rossum MM, van Erp PE, et al. Changes in keratin 6 and keratin 10 (co-)expression in lesional and symptomless skin of spreading psoriasis. Dermatology 2000; 201 (1): 15-20
20. Altmeyer P, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-981
21. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998; 138 (3): 456-460
22. Skaria AM, Schmid U. Antipsoriatic effect of fumaric acid derivatives. J Am Acad Dermatol 1996; 34 (2): 323-324
23. Nowack U, Gambichler T, Hanefeld C, et al. Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol 2002; 24 (2): 15
24. Treumer F, Zhu K, Glaser R, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121 (6): 1383-1388
25. Bacharach-Buhles M, Rochling A, el Gammal S, et al. The effect of fumaric acid esters and dithranol on acanthosis and hyperproliferation in psoriasis vulgaris. Acta Derm Venereol 1996; 76 (3): 190-193
26. Sebok B, Szabados T, Kerenyi M, et al. Effect of fumaric acid, its dimethylester, and topical antipsoriatic drugs on epidermal differentiation in the mouse tail model. Skin Pharmacol 1996; 9 (2): 99-103
27. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001; 116 (2): 203-208
28. Ockenfels HM, Schultewolter T, Ockenfels G, et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139 (3): 390-395
29. Loewe R, Holnthoner W, Groger M, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168 (9): 4781-4787
30. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.Dermatology 1998; 196 (2): 223-230
31. Bacharach-Buhles M, Pawlak F, Matthes U, et al. Fumaric acid esters (FAEs) suppress CD 15- and ODP 4-positive cells in psoriasis. Acta Derm Venereol 1994; 186: 79-82
32. Fredriksson T, PetterssonU. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244
33. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-1110
34. Takeda KG, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993; 177: 155-162
35. Wilson SB,Kent SC, Patton KT, et al. Extreme Th1 bias of invariant Va24JaQ T cells in type 1 diabetes. Nature 1998; 391: 177-184
36. Lehuen A, Lantz O, Beaudoin L, et al. Overexpression of natural killer T cells protects Va14-Ja281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188: 1831-1839